Wednesday, 22 May 2019

You are here

ACR Says the New AHCA is Insufficient for Arthritis Patients

Dr. Sharad Lakhanpal, MBBS, MD, President of the American College of Rheumatology (ACR) has issued a press release condeming the insufficiencies of the newly proposed American Health Care Act (AHCA).

The ACR has studied the AHCAA and are encouraged by no exclusions for pre-existing illness, continued limits on patient copayments, caps on out-of-pocket costs, coverage for children on a parent’s insurance until age 26, and a ban on lifetime limits.

The ACR's focus is to ensure Americans have continued access to rheumatology care that lowers long-term costs and helps patients manage pain, avoid long-term disability, remain active in the workforce, and preserve their quality of life. 

Dr. Lakhanpal believes this legislation will hurt patients and rheumatology care.  Objections include:

  • proposed tax credits based on age rather than income
  • allowances for insurers to impose a 12 month 30% premium increase when there is a lapse in coverage >63 days.
  • non-recognition of ACR’s recommendations to minimize the administrative burden on doctors and to repeal the Independent Payment Advisory Board (IPAB).

“We look forward to working with Congressional leaders and the Administration to address these concerns and will continue to provide input on proposed legislation to ensure continued access to vital rheumatology healthcare services,” says Dr. Lakhanpal.

 

 

- See more at: http://www.rheumatology.org/About-Us/Newsroom/Press-Releases/ID/798/ACR-...

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Steroids, Not Biologics, Drive Arthroplasty Infections in RA

Medicare and Truven MarketScan administrative data study (2006 through 2015) of rheumatoid arthritis (RA) undergoing arthroplasty found that while that the risks of perioperative infection was similar across biologics, the infection risk with glucocorticoid use, especially at > 10 mg/d, was significantly greater.

Generic Price Fixing Alleged by State Prosecutors

The NY Times and 60 Minutes have reported that Connecticut, along with 43 other states, filed a mega-lawsuit accusing the generic drug makers of a massive, systematic conspiracy to bilk consumers out of billions of dollars. (Citation source: https://buff.ly/2vSmv03)

Drug Pricing Regulations in US and Canada

Reuters reports on regulatory efforts by Canada and the US to curb the rising cost of drugs, especially expensive new medicines. 

In Canada, a little-known government agency is increasing its oversight of expensive drugs sold in Canada. The federal Patented Medicine Prices Review Board (PMPRB) is targeting an increasing number of expensive drugs introduced in the last several years by drug makers.

Nonadherence is Costly for Patients in Pain

A comparative cohort study of patients with osteoarthritis (OA), gout, diabetic peripheral neuropathy (pDPN), post-herpetic neuralgia (PHN), and fibromyalgia (FM) shows that nonadherence to pain medications is high and leads to greater overall health care resource utilization and costs. 

Naproxen has no Effect on Alzheimer's

A randomized controlled trial shows that chronic low-dose naproxen does not reduce progression of presymptomatic Alzheimer disease (AD).

The INTREPAD trial was a 2-year double-masked prevention trial, that enrolled 195 AD who were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score (APS).